Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.146593210.3389/fphar.2024.1465932PharmacologyCorrectionCorrigendum: Nonmuscle myosin heavy chain IIA-mediated exosome release via regulation of the rho-associated kinase 1/myosin light chains/actin pathwayLv et al.10.3389/fphar.2024.1465932LvYanni1ChenJin2*HuJinfang1QianYisong3KongYing1FuLongsheng11Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Jiangxi, China2Department of Neurology, The First Affiliated Hospital of Nanchang University, Jiangxi, China3Institute of Translational Medicine, Nanchang University, Nanchang, China
Edited and reviewed by:Maria Angela Sortino, University of Catania, Italy
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Nonmuscle myosin heavy chain IIA-mediated exosome release via regulation of the rho-associated kinase 1/myosin light chains/actin pathway by Lv Y, Chen J, Hu J, Qian Y, Kong Y and Fu L (2020). Front. Pharmacol. 11:598592. doi: 10.3389/fphar.2020.598592nonmuscle myosin heavy chain IIAexosome releaserho-associated kinase 1/myosin light chains/actinmicroglial cellslipopolysaccharidesection-at-acceptanceExperimental Pharmacology and Drug Discovery
In the published article, there was an error in Figure 2 as published. In Figure 2B, the panel representing CD18 in the LPS+blebbisatin group was a repeat of the panel representing CD9 in the LPS+blebbisatin group. The corrected Figure 2 and its caption appear below.
The myosin inhibitor, blebbistatin, inhibited exosome release from microglial cells under the stimulation of LPS. The extracted exosomes were divided into those extracted from control microglial cells, microglial cells incubated with 1 mg/mL LPS for 24 h, and microglial cells added with 1 μM blebbistatin 0.5 h before the 24 h stimulation of LPS. (A) Nanoparticle tracking analysis for the concentration of exosomes. (B) Flow cytometry analysis for CD9-labeled positive rate, CD81-labeled positive rate, or control FITC-IgG-labeled positive rate. (C) The protein expression levels of CD9 and CD81 exosome marker proteins were examined by Western blot. Western blots were quantified. Nine independent experiments were analyzed. A histogram depicts the quantitative representation of CD9 and CD81 protein expression for each group. The data were averages ±SD, n = 9. **p < 0.01 vs. control microglial cells; ##p < 0.01 vs. microglial cells stimulated with LPS.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.